SEMA3A and cancer: Findings from preclinical studies spurred several clinical trials aimed at investigating the diagnostic efficiency or the potential role as a relapse or proliferation biomarker or indicator of response to cancer therapy of selected semaphorins/receptors, mostly represented by Sema3A, Sema4C and neuropilin1.